Q-omics provides the consensus-scored DENND4C profile across patient tissues and cancer cell-line models. DENND4C expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DENND4C is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, DENND4C RNA expression shows 20,982 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUSC, and THYM as cancer lineages where DENND4C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DENND4C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DENND4C survival associations across molecular data types. DENND4C RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DENND4C RNA expression–survival associations across cancer types. High DENND4C expression shows unfavorable associations in ESCA and CESC, but favorable associations in KIRC, SKCM, READ and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DENND4C RNA expression.
This table summarizes DENND4C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 8. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DENND4C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DENND4C shows lower tumor expression in LUSC, UCEC, THCA, BRCA and LUAD and higher tumor expression in KIRP. The LUSC box plot shows higher DENND4C RNA expression in normal versus tumor tissue (log2 FC = −1.518, t-test p < 0.001).
This table shows molecular features associated with DENND4C in patient tissues and cancer cell lines. In patient samples, DENND4C shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DENND4C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
